Article Information
History
- August 11, 2020.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Daniel Wrighta,b,*,
- Elizabeth R. Allenc,
- Madeleine H.A. Clarkd,
- John N. Gitongaa,
- Henry K. Karanjaa,
- Ruben Hulswitc,
- Iona Taylorb,
- Sumi Biswasb,
- Jennifer Marshallb,
- Damaris Mwololoe,
- John Muriukie,
- Bernard Bette,
- Thomas A. Bowdenc and
- George M. Warimwea,f
- aKEMRI-Wellcome Trust Research Programme, Kenya
- bThe Jenner Institute, University of Oxford, UK
- cWellcome Centre for Human Genetics, Division of Structural Biology, University of Oxford, UK
- dLondon School of Hygiene & Tropical Medicine, UK
- eInternational Livestock Research Institute, Kenya
- fCentre for Tropical Medicine and Global Health, University of Oxford, UK
- ↵* Corresponding author; email: danny.wright{at}ndm.ox.ac.uk
Posted August 11, 2020.
Naturally acquired Rift Valley fever virus neutralizing antibodies predominantly target the Gn glycoprotein
